Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment

Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50. Treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapies and hormone therapy. Although chemotherapy is not systematically used, it remains a frequent treatment option. While chemotherapy makes a major contribution to curing cancer, it is also a source of potentially disabling side effects for survivors. Chemotherapy can interfere with the n

Trial Details

NCT ID
NCT06995443
Phase
NA
Sponsor
Centre Hospitalier de Valenciennes
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Photobiomodulation
Locations (sample)
  • Valenciennes, France|50.35909,3.52506

Key Eligibility Criteria

  • Women aged 18 and over
  • Having completed chemotherapy (intravenous) for breast cancer (any stage) less than 12 months prior to inclusion
  • Having a perceived cognitive complaint that appeared during or after (\< 3 months) chemotherapy treatments (no restriction on the care protocol use…
  • Patient eligible for photobiomodulation sessions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →